BeOne invests $300 million in New Jersey plant, adding small-molecule capacity and 120 jobs
BeOne Medicines announced a $300 million investment to expand its manufacturing campus in Hopewell, New Jersey.
The expansion will include a three‑story, 145,000‑square‑foot building for small‑molecule production and packaging, complementing its existing biologics operations.
The new capacity is aimed at supporting the company’s hematology portfolio, including the BTK inhibitor Brukinsa and the investigational BTK degrader tacabrutideg, and may accommodate future collaborations.
The project is expected to create about 120 new jobs and brings total investment in the campus to over $1 billion since its opening in 2024.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “BeOne commits $300M to US manufacturing expansion, creating 120 new jobs”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that